Theyre FDA approved for diabetes and obesity, respectively
Pegington M, Harvie M, Harkness EF, Brentnall A, Malcomson L, Southworth J, Fox J, Howell A, Cuzick J, Evans DG (2023) Obesity at age 20 and weight gain during adulthood increase risk of total and premature all-cause mortality: findings from women attending breast screening in Manchester
Unlike traditional anti-angiogenic therapies that target VEGF, Sylentis developed SYL1801, an siRNA targeting NOTCH Regulated Ankyrin Repeat Protein (NRARP), to prevent and control nAMD progression
Turnage and the team understand that losing excess weight is a critical part of overall wellness and aids in longevity for the years to come
The pharmacokinetic groundwork that is also missing Even before an efficacy trial, injectable GHK-Cu lacks the basic human pharmacokinetic characterization that any injectable drug candidate would require: measured plasma half-life of the intact complex, the fraction of administered copper that binds to plasma proteins versus remains peptide-bound, tissue distribution, and how much functional complex if any actually reaches the dermis
p = 0.02 [50]
